Clinigen Group (OTCMKTS:CLIGF) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Clinigen Group (OTCMKTS:CLIGF) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of CLIGF stock opened at $12.90 on Tuesday. The company has a 50 day moving average of $12.90. Clinigen Group has a twelve month low of $9.87 and a twelve month high of $12.90.

Featured Story: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Clinigen Group  Upgraded at Zacks Investment Research
Clinigen Group Upgraded at Zacks Investment Research
CHINA COAL ENER/ADR  Upgraded by Zacks Investment Research to Buy
CHINA COAL ENER/ADR Upgraded by Zacks Investment Research to Buy
CHINA COMMUNICA/ADR  Upgraded to “Hold” by Zacks Investment Research
CHINA COMMUNICA/ADR Upgraded to “Hold” by Zacks Investment Research
Bank of East Asia  Upgraded to Hold at Zacks Investment Research
Bank of East Asia Upgraded to Hold at Zacks Investment Research
Bay Banks of Virginia  Upgraded by Zacks Investment Research to Buy
Bay Banks of Virginia Upgraded by Zacks Investment Research to Buy
Aerpio Pharmaceuticals  Lowered to Hold at Zacks Investment Research
Aerpio Pharmaceuticals Lowered to Hold at Zacks Investment Research


© 2006-2019 Ticker Report